Date: 2015-02-23
Type of information: Nomination
Compound:
Company: Summit Therapeutics (UK)
Therapeutic area: Infectious diseases - Neuromuscular diseases - Rare diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On February 23, 2015, Summit Therapeutics, a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy and C. difficile infection, announces the appointment of Mr David Wurzer as a Non-Executive Director. David Wurzer (aged 56) has extensive experience in business and financial matters relating to the pharmaceutical and biotechnology sector having held a number of senior executive and board level positions. Mr Wurzer was Executive Vice President, Treasurer and Chief Financial Officer of the NASDAQ listed biotechnology company CuraGen Corporation from 1997 to 2008. He also held a number of positions at Value Health Inc., from 1991 to 1997 including Senior Vice President, Treasurer and Chief Financial Officer. He is currently the Executive Vice President and Chief Investment Officer at Connecticut Innovations, a state funded venture capital fund. Mr. Wurzer is currently a Non-Executive Director on the boards of Response Genetics and Special Diversified Opportunities, Inc., and from 2010 to 2012 he was a Non-Executive Director on the board of DUSA Pharmaceuticals.
Financial terms:
Latest news:
